
    
      This multicentre, prospective, observational study will describe the treatment and clinical
      outcomes of of dialysis patients in South Africa. No formal hypothesis will be tested in this
      descriptive study. Eligible subjects will be receiving either peritoneal or haemodialysis,
      will have received Aranesp therapy between 3 and 6 months prior to enrolment into the study,
      do not need to be receiving Aranesp at the time of enrolment and will be followed for up to
      12 months after commencement of Aranesp. Data to be collected includes ESA therapies, iron
      usage, relevant concomitant therapies, haemoglobin concentrations, other relevant clinical
      laboratory parameters and red cell transfusions.
    
  